Farmiver 100mg, 200mg 10 ml SUSP, Albendazole, Quinfamide
Famacéutica Form and Formulation
Each bottle contains:
Dosage and administration
Oral Dosage: Children: Children 4-6 years: 10 ml of the suspension (100 mg and 200 mg quinfamida albendazole) as a single dose. Junior: Children 7 to 11 years: 20 ml of the suspension (200 mg and 200 mg quinfamida albendazole) ..
INDICATIONS: OXAL is indicated in chronic intestinal amebiasis, acute intestinal amebiasis and amebic dysentery caused by Entamoeba histolytica.
Helminthiasis: OXAL is an effective anthelmintic against nematodes and tapeworms, indicated for the treatment of enterobiasis and ascariasis, strongyloidiasis, uncinariosis, whipworm, and himenolepiosis teniosis.
Pharmacokinetics: The quinfamida is a dicloroacetilquinolinol whose chemical name is 1- (DICHLOROACETYL) 1,2,3,4-tetrahidroquinolinol-2-furancarboxylate. Its mechanism of action is not fully understood, however recent research has shown that exerts its effect by immobilizing amebicide trophozoites, thus preventing its spread. Only acts at the intestinal lumen.
Preclinical pharmacology studies have shown that quinfamida, after oral administration, is poorly absorbed and irregularly in the gastrointestinal tract. The maximum serum concentration is reached at 7 hours after administration.
After 24 hours, the quinfamida is excreted renally (50%) and feces (50%). In vitro studies in human whole blood, have shown that the fraction of the dose is reached quinfamida absorb, is hydrolysed in less active metabolites after two minutes.
The quinfamida acts on the mobile forms of Entamoeba histolytica (trophozoites) present in the intestinal lumen. Acts only on the intraluminal intestinal amebiasis, which should not be used to treat intestinal amebiasis such as patients with liver abscess.
Albendazole is a benzimidazole anthelmintic with activity. After oral administration, albendazole is absorbed in small intestine. A dose of 6.6 mg / kg albendazole, the plasma concentration of its main metabolite albendazole sulfoxide, reaches a maximum of 0.25 to 0.30 g / ml after two hours. The half-life in plasma albendazole is 8.5 hours.
The metabolite is eliminated in urine. Albendazole is anthelmintic effect by inhibiting tubulin polymerization and thus abate energy levels insufficient for the survival of the parasites amount. It is vermicida larvicide. Thus, albendazole initially immobilized and then kill susceptible helminths.
In the case of Giardia lamblia the effects of albendazole on trophozoites are manifested by alterations in the main component that is already tubulin microfilaments (microstrip) whose component is giardina conditioning a disorganization of the cytoplasm (morphological alteration of the parasite), dislocation the ventral disc with loss of viability.
There is also evidence that the drug causes loss of adhesion of trophozoites to the intestinal walls.
Contraindications: Contraindicated in patients enrolled with hypersensitivity to quinfamida acetilquinolinol or derivatives in extraintestinal amebiasis, amebic dysentery severe, pregnancy, lactation in patients with hypersensitivity to the components of the formula. Children under 2 years of age.
PRECAUTIONS: None in particular.
RESTRICTIONS OF USE DURING PREGNANCY AND BREASTFEEDING
To date there are no data on the safety of quinfamida in pregnancy and lactation, therefore, the benefits must be weighed against the potential risks when using the drug in these circumstances.
Albendazole is known to be teratogenic and embryotoxic in mice and rabbits, therefore, should not be administered during pregnancy. In women of childbearing age should be administered within seven days of onset of menstruation or after having a negative pregnancy test and advised to take contraceptive precautions for a month after completion of treatment.
Is not known whether albendazole or its metabolites are excreted in human milk.
Therefore, albendazole should not be used during lactation unless it is considered that the potential benefits outweigh the potential risks associated with treatment.
ADVERSE REACTIONS: In some patients who have been treated with quinfamida, have observed the following effects: headache, nausea and abdominal pain, which have been mild and transient. Also reported rarely vertigo.
DRUG INTERACTIONS: So far there are no data quinfamida interaction with other drugs.
Praziquantel increases plasma levels of albendazole.
CHANGES IN RESULTS OF LABORATORY TESTS: No data on changes in laboratory tests using quinfamide.
RECOMMENDED STORAGE: Store at room temperature to no more than 30 ° C temperature.
MANIFESTATIONS AND MANAGEMENT OF OVERDOSE OR ACCIDENTAL INGESTION: In case of overdose control measures should be as close observation of the patient, symptomatic measures (gastric lavage), and general supportive treatment.
PRECAUTIONS IN RELATION TO EFFECTS Carcinogenesis, Mutagenesis, Impairment of Fertility: mutagenicity studies conducted in animals have reported negative data. Albendazole has teratogenic and embryotoxic effects in rats and rabbits. In toxicity studies in rats and mice with daily doses above 30 times the recommended human dose, tumor formation was not related to treatment were observed.
Infant Suspension: Bottle with 10 ml (100 mg and 200 mg quinfamida albendazole).
Junior Suspension: Bottle with 20 ml (200 mg and 400 mg quinfamida albendazole)
Drug Name: FARMIVER
Comparative Brand: VERMOX
Active ingredient: albendazole quinfamide-
Concentration: 200/400 mg
Response time: No
Laboratory FARMACOS CONTINENTAL, SA de CV
Box with pot suspencion
Manufactured in: Mexico